Pompe Disease Stocks ListRelated Stock Lists: Cancer Enzyme Replacement Therapy Gaucher Disease Inborn Errors Of Metabolism Medicine Rare Diseases Achondroplasia Autoimmune Disease Biomarin Pharmaceutical Biopharmaceutical Biopharmaceuticals Bristol Myers Squibb Cac 40 Chronic Kidney Disease Colorectal Cancer Consumer Health Care Products Deep Vein Thrombosis Dialysis Drug Discovery Enzyme Replacement Therapies
|2020-05-27||BMRN||New 52 Week Closing High||Bullish|
|2020-05-27||BMRN||Upper Bollinger Band Walk||Strength|
|2020-05-27||BMRN||Jack-in-the-Box Bullish||Bullish Swing Setup|
|2020-05-27||FOLD||20 DMA Support||Bullish|
|2020-05-27||FOLD||Slingshot Bullish||Bullish Swing Setup|
|2020-05-27||FOLD||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup|
|2020-05-27||FOLD||180 Bullish Setup||Bullish Swing Setup|
|2020-05-27||SNY||Cup with Handle||Other|
Glycogen storage disease type II, also called Pompe disease, is an autosomal recessive metabolic disorder which damages muscle and nerve cells throughout the body. It is caused by an accumulation of glycogen in the lysosome due to deficiency of the lysosomal acid alpha-glucosidase enzyme. It is the only glycogen storage disease with a defect in lysosomal metabolism, and the first glycogen storage disease to be identified, in 1932 by the Dutch pathologist J. C. Pompe.
The build-up of glycogen causes progressive muscle weakness (myopathy) throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver and the nervous system.